Skip to content
Linkedin page opens in new windowLinkedin page opens in new window
Therawis
therapies wisely applied
TherawisTherawis
  • Home
  • About
  • Therawis Pharma
    • Management
    • Clinical Services
  • Therawis Diagnostics
    • Management
    • Diagnostics
      • Pipeline
      • therascreen PITX2
      • ExosomeDx
      • Platin-R
    • Publications
    • Press Releases
    • Investigator Login
  • Partners
  • Contact
Search:
  • Home
  • About
  • Therawis Pharma
    • Management
    • Clinical Services
  • Therawis Diagnostics
    • Management
    • Diagnostics
      • Pipeline
      • therascreen PITX2
      • ExosomeDx
      • Platin-R
    • Publications
    • Press Releases
    • Investigator Login
  • Partners
  • Contact

Press Releases

You are here:
  1. Home
  2. Press Releases

Therawis Diagnostics' licensing and development partner QIAGEN launches predictive therascreen PITX2 test in Europe to guide treatment in high-risk breast cancer.

February 7, 2018

Therawis Diagnostics and QIAGEN enter into a development and commercialization agreement on predictive biomarkers in oncology.

May 26, 2016
© Therawis - 2020
  • Disclaimer
  • Privacy Policy
  • Legal Notice
  • Cookie Policy (EU)
Info
Go to Top